List of Wynzora drug patents
Wynzora is owned by Mc2.
Wynzora contains Betamethasone Dipropionate; Calcipotriene.
Wynzora has a total of 1 drug patent out of which 0 drug patents have expired.
Wynzora was authorised for market use on 20 July, 2020.
Wynzora is available in cream;topical dosage forms.
The generics of Wynzora are possible to be released after 27 September, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10265265 | MC2 | Topical composition |
Sep, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Dosage Form (NDF) | Jul 20, 2023 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient
Market Authorisation Date: 20 July, 2020
Treatment: NA
Dosage: CREAM;TOPICAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic